Day Three arrives and Reuters Pharma 2023 comes to a close – but not before Boehringer Ingelheim talks to us about accelerating time-to-patient and an expert panel discusses empowering a wh
Armed with new phase 3 data, Bayer has started preparing filings for elinzanetant as a treatment for vasomotor symptoms (VMS) associated with menopause, setting up a chall
The UK is welcoming a new era of clinical trial delivery, evolving beyond the traditional site-centric approach to also embrace remote, decentralised, virtual, and hybrid trials and enablin